SCM
TARA icon

Sterling Capital Management’s Protara Therapeutics TARA Stock Holding History

Sterling Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.03K Sell
1,055
-648
-38% -$3.08K ﹤0.01% 2738
2026
Q1 		$8.87K Sell
1,703
-329
-16% -$1.95K ﹤0.01% 2438
2025
Q4 		$10.8K Sell
2,032
-197
-9% -$1.09K ﹤0.01% 2565
2025
Q3 		$9.7K Buy
2,229
+1,357
+156% +$4.39K ﹤0.01% 2500
2025
Q2 		$2.64K Buy
+872
New +$3.01K ﹤0.01% 2838

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Sterling Capital Management's TARA Position: Q2 2026 in Review

Sterling Capital Management reduced its Protara Therapeutics (TARA) stake by 38% in Q2 2026, selling an estimated $3.08K and leaving 1,055 shares worth $4.03K. The position accounts for ﹤0.01% of the portfolio, ranked #2738.

Sterling Capital Management first reported a position in TARA in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.8K in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Sterling Capital Management held 1,055 shares of Protara Therapeutics worth $4.03K as of Q2 2026.
  • Sterling Capital Management sold 648 Protara Therapeutics shares in Q2 2026, an estimated $3.08K.
  • Protara Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2738 holding.
  • Sterling Capital Management first reported a position in Protara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Protara Therapeutics position peaked at $10.8K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.